Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00008450
Other study ID # 1227.00
Secondary ID NCI-2010-0204512
Status Completed
Phase Phase 1
First received
Last updated
Start date August 11, 1997
Est. completion date December 26, 2018

Study information

Verified date July 2019
Source Fred Hutchinson Cancer Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot clinical trial studies total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients with severe combined immunodeficiency (SCID) undergoing donor bone marrow transplant. Giving total-body irradiation (TBI) before a donor bone marrow transplant using stem cells that closely match the patient's stem cells, helps stop the growth of abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may mix with the patient's immune cells and help destroy any remaining abnormal cells. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from happening.


Description:

PRIMARY OBJECTIVES:

I. To safely establish partial lymphoid chimerism (1-95% donor cluster of differentiation [CD]3+ cells) using a non-lethal conditioning regimen in patients with severe combined immunodeficiency syndrome.

II. To define the kinetics of immune reconstitution following a non-lethal conditioning regimen in patients with immunodeficiency diseases.

OUTLINE:

Patients receive cyclosporine orally (PO) or intravenously (IV) on days -3 to 100 followed by a taper until day 180 and mycophenolate mofetil PO or IV on days 0-40 with a taper until day 96 in the absence of unacceptable toxicity. Unrelated donor recipients also undergo TBI on day 0. Patients undergo bone marrow transplant on day 0.

After completion of study treatment, patients are followed up at 6 months and then yearly for 5 years.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date December 26, 2018
Est. primary completion date October 25, 2011
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients with severe combined immunodeficiency syndrome:

- SCID with presence of B lymphocytes

- X-linked SCID (presence of B lymphocytes)

- Autosomal recessive SCID

- Patients with severe combined immunodeficiency syndrome:

- SCID with absence of T and B lymphocytes

- Patients with severe combined immunodeficiency syndrome:

- Purine metabolite deficiencies, deficiencies of the purine metabolites

- Adenosine deaminase (ADA) deficiency

- Purine nucleoside phosphorylase (PNP) deficiency

- DONOR: Related donor who is human leukocyte antigen (HLA) genotypically identical at least at one haplotype and may be genotypically or phenotypically identical for serological typing for HLA-A, B, C, and at the allele level for DRB1 and DQB1; related donors other than siblings must be matched at HLA-A, B, and C (at highest resolution available at the time of donor selection) and at DRB1 and DQB1 by deoxyribonucleic acid (DNA) typing; if more than one HLA-identical sibling is available, priority will be given to the oldest normal donor

- DONOR: Unrelated donors who are prospectively matched for HLA-A, B, C, DRB1 and DQB1 by DNA typing at the highest resolution routinely available at the time of donor selection; only a single allele disparity will be allowed for HLA-A, B, or C as defined by high resolution typing

Exclusion Criteria:

- Patients with viral associated T cell immunodeficiency disorders, such as human immunodeficiency virus (HIV)

- Patients with other disease or organ dysfunction that would limit survival to less than 30 days

- DONOR: Identical twin

- DONOR: Pregnancy

- DONOR: HIV seropositive

- DONOR: A positive anti-donor cytotoxic cross match is absolute donor exclusion

- DONOR: Patient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-HLA allele mismatch, i.e., the patient is A*0201, and this type of mismatch is not allowed

- DONOR: < 6 months old, > 75 years old

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Allogeneic Bone Marrow Transplantation
Undergo allogeneic bone marrow transplant
Drug:
Cyclosporine
Given PO or IV
Other:
Laboratory Biomarker Analysis
Correlative studies
Drug:
Mycophenolate Mofetil
Given PO or IV
Procedure:
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Undergo nonmyeloablative allogeneic hematopoietic stem cell transplant
Radiation:
Total-Body Irradiation
Undergo TBI

Locations

Country Name City State
United States Fred Hutch/University of Washington Cancer Consortium Seattle Washington

Sponsors (3)

Lead Sponsor Collaborator
Fred Hutchinson Cancer Research Center National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mixed hematopoietic chimerism in a population of pediatric patients with immunodeficiency diseases It will be established whether a non-lethal conditioning regimen can successfully induce mixed hematopoietic chimerism in a population of pediatric patients with immunodeficiency diseases, without adverse effects on mortality. Up to 5 years
See also
  Status Clinical Trial Phase
Completed NCT00006335 - Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID N/A
Not yet recruiting NCT02231983 - Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China N/A
Active, not recruiting NCT03597594 - Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) Phase 1/Phase 2
Completed NCT00000603 - Cord Blood Stem Cell Transplantation Study (COBLT) Phase 2
Completed NCT00001255 - Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study N/A
Recruiting NCT05651113 - The Experience of Screening for SCID
Completed NCT00794508 - MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID Phase 2
Recruiting NCT03538899 - Autologous Gene Therapy for Artemis-Deficient SCID Phase 1/Phase 2
Recruiting NCT05298930 - Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Completed NCT00845416 - Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population N/A
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A
Completed NCT03878069 - Registry Study of Revcovi Treatment in Patients With ADA-SCID
Recruiting NCT01019876 - Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases Phase 2/Phase 3
Completed NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Phase 1/Phase 2
Withdrawn NCT02177760 - Sirolimus Prophylaxis for aGVHD in TME SCID Phase 2
Recruiting NCT00695279 - Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
Completed NCT01420627 - EZN-2279 in Patients With ADA-SCID Phase 3
Terminated NCT02127892 - SCID Bu/Flu/ATG Study With T Cell Depletion Phase 1/Phase 2
Completed NCT04246840 - Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft